Reported cases in allergy centers
Of the 334 , 214 experienced any symptom in line with a possible
allergic reaction after receiving a SARS-CoV-2 vaccination and five
patients experienced symptoms in line with a possible allergic reaction
after receiving the second vaccine dose. Out of these, 195 reactions
occurred after the first application of an mRNA-based vaccine (157
Comirnaty®, and 38 Spikevax®) and eighteen reactions were reported from
patients after application of a vector vaccine (Vaxzevria®) (figure 1).
One patient had a reaction after the first dose of an unknown SARS-CoV-2
vaccination (Sup.Table 3). 115/334 included individuals had a positive
allergy history and presented for the assessment of the risk to develop
hypersensitivity reactions during SARS-CoV-2 vaccination. Of note, we
only included those patients who underwent allergy testing in this
analysis. Hundreds of patients more presented to the allergy centers
with alleged SARS-CoV-2 vaccination reactions, but after taking a
detailed history their symptoms were not considered to be allergic and
further allergy work-up was omitted. Figure 2 shows a workflow of our
study.